Deuterated hpk1 kinase inhibitor, and preparation method therefor and use thereof

A compound of general formula I,

• wherein,
• A is selected from CR10 and N;
• Q is selected from O and S;
• x and z are independently selected from integers between 0 and 6;
• y is 0 or 1;
• Ar is selected from aromatic five-membered heterocyclic group, aromatic six-membered heterocyclic group and phenyl, wherein the aromatic five-membered heterocyclic group is selected from:
• furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl and selenothiazolyl, and the aromatic six-membered heterocyclic group is selected from:
• pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl;
• optionally, H on the aromatic five-membered heterocyclic group, the aromatic six-membered heterocyclic group or the phenyl may be substituted with the following groups:
• -D, —SO2, —SO2N(C0-10 alkyl)(C0-10 alkyl), —N(C0-10 alkyl)SO2(C0-10 alkyl), —CON(C0-10 alkyl)(C0-10 alkyl), —N(C0-10 alkyl)CO(C0-10 alkyl), —N(C0-10 alkyl)COO(C0-10 alkyl), —OCON(C0-10 alkyl)(C0-10 alkyl), halogen, —CN, —OCH2F, —OCHF2, —OCF3, C1-10 linear/branched alkyl, —N(C0-10 alkyl)(C0-10 alkyl), —OC0-10 alkyl, C3-10 cycloalkyl, —O heterocycloalkyl, —N heterocycloalkyl, —N heterocycloaryl, —O heterocycloaryl or —S heterocycloaryl, and wherein the alkyl moieties may be optionally substituted with one or more of the following groups:
• —SO2, —SO2N(C0-10 alkyl)(C0-10 alkyl), —N(C0-10 alkyl)SO2(C0-10 alkyl), —CON(C0-10 alkyl)(C0-10 alkyl), —N(C0-10 alkyl)CO(C0-10 alkyl), —N(C0-10 alkyl)COO(C0-10 alkyl), —OCON(C0-10 alkyl)(C0-10 alkyl), halogen, —CN, —OCH2F, —OCHF2, —OCF3, —N(C0-10 alkyl)(C0-10 alkyl), —OC0-10 alkyl, —CO(C0-10 alkyl), —COO(C0-10 alkyl), —N heterocycloaryl, —O heterocycloaryl or —S heterocycloaryl, wherein one or more H atoms attached to the C atoms or heteroatoms may be substituted with deuterium;
• R2 is selected from:
• —H, -D, halogen, —NO2, —CN, C1-10 linear/branched alkyl, C3-10 cycloalkyl, —N(C0-10 alkyl)(C0-10 alkyl), —CF3, —OCF3, —OCHF2, —OCH2F and —OC0-10 alkyl, wherein one or more H atoms attached to the C atoms may be substituted with deuterium;
• B1, B2, B3, B4 and B5 are independently selected from C and N;
• R3, R4, R5, R6 and R7 are independently selected from:
• —H, -D, halogen, —CN, —OC0-10 alkyl, —CO(C0-10 alkyl), —CON(C0-10 alkyl)(C0-10 alkyl), C1-10 linear/branched alkyl, heteroalkyl containing 0 and N, —N(C0-10 alkyl)(C0-10 alkyl), C3-10 cycloalkyl, —C≡C—R10, —O heterocycloalkyl and —N heterocycloalkyl, or R5 and R4, R4 and R3, R3 and R7, R7 and R6, together with carbon atoms therebetween, form C3-8 cycloalkyl or C3-8 heterocycloalkyl containing —O— or —S—, —N heterocycloaryl, —O heterocycloaryl, —S heterocycloaryl or phenyl, wherein one or more H atoms attached to the C atoms or heteroatoms may be substituted with deuterium;
• R8 and R9 are independently selected from:
• —H, -D, halogen and C1-10 linear/branched alkyl, wherein one or more H atoms attached to the C atoms may be substituted with deuterium;
• R10 is selected from:
• —H, -D, C1-5 linear/branched alkyl, C3-10 cycloalkyl and
• wherein one or more H atoms attached to the C atoms may be substituted with deuterium;
• R11 and R12 are independently selected from:
• —H, -D, —CF3, —CHF2, —CH2F, C1-10 linear/branched alkyl, —CH═C(C0-10 alkyl)(C0-10 alkyl), —C≡C(C0-10 alkyl), C3-10 cycloalkyl, an aromatic five-membered cyclic group and an aromatic six-membered cyclic group, or R11 and R12, together with carbon atoms between R11 and R12, form C3-8 cycloalkyl or C3-8 heterocycloalkyl containing —O— or —S—, C4-9 fused cycloalkyl, C5-10 spiro cycloalkyl, C4-9 bridged cycloalkyl, C3-7 cyclolactam, C3-7 cyclic lactone or C3-7 cyclic ketone, wherein one or more H atoms attached to the C atoms or heteroatoms may be substituted with deuterium;
• and the compound of general formula I contains at least one deuterium atom;
• or a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug and a solvate thereof.